Developing new drugs to treat Alzheimer's disease by targeting a specific protein.
Development of PU.1 Inhibitory Modulators as Novel Therapeutics for Alzheimer's Disease
This study is looking at a new type of medicine that could help delay Alzheimer's disease by targeting a specific protein in brain cells, and it's designed for people who are at risk of developing the condition.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts Institute of Technology NIH-funded |
| Lab location | 1 site (Cambridge, United States) |
| Project ID | NIH-10853048 on NIH RePORTER |
What this research studies
This research focuses on creating new therapeutic agents called PU.1 Inhibitory Modulators (PIMs) to combat Alzheimer's disease (AD). The approach is based on understanding how microglia, a type of brain cell, contribute to the progression of AD, particularly through the action of the protein PU.1. By inhibiting PU.1, the researchers aim to delay the onset of Alzheimer's in individuals at risk. The project involves collaboration between scientists and industry experts to ensure effective drug development.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk of developing Alzheimer's disease, particularly those with a family history or genetic predisposition.
Not a fit: Patients who are already diagnosed with advanced Alzheimer's disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly delay the onset of Alzheimer's disease in at-risk individuals.
How similar studies have performed: Other research has shown promise in targeting microglial activity for Alzheimer's treatment, suggesting that this approach could be a viable new strategy.
Where this research is happening
Cambridge, United States
- Massachusetts Institute of Technology — Cambridge, United States (Active)
Researchers
- Principal investigator: Tsai, Li-Huei — Massachusetts Institute of Technology
- Study coordinator: Tsai, Li-Huei
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.